Table 5

Results from Cox regression models in subgroups considering both the presence of CAD versus PAD and the presence of T2DM

CADPAD
T2DM−T2DM+T2DM−T2DM+
3-point MACE1.57 (1.21 to 2.03)1.50 (1.09 to 2.06)2.94 (2.18 to 3.97)
3-point MACE*1.27 (0.93 to 1.79)1.28 (0.91 to 1.79)2.18 (1.49 to 3.18]
Vascular mortality2.00 (1.40 to 2.85)1.46 (0.91 to 2.33)3.22 (2.13 to 4.89)
Vascular mortality*1.70 (1.08 to 2.70)1.30 (0.78 to 2.16)2.13 (1.25 to 3.63)
Stroke1.36 (0.84 to 2.20)1.73 (1.01 to 2.97)2.24 (1.93 to 5.43)
Stroke*1.05 (0.57 to 1.92)1.47 (0.82 to 2.61)2.00 (1.02 to 3.91)
MCI1.32 (0.84 to 2.08)2.32 (1.48 to 3.65)3.03 (1.86 to 4.95)
MCI*1.17 (0.68 to 2.01)1.88 (1.15 to 3.07)2.44 (1.33 to 4.49]
All-cause mortality1.60 (1.29 to 2.00)1.69 (1.29 to 2.20)2.67 (2.04 to 3.48)
All-cause mortality*1.30 (0.98 to 1.72)1.37 (1.03 to 1.82)1.58 (1.13 to 2.20)
  • *Adjustments were made for age, gender, BMI, history of smoking, arterial hypertension, systolic blood pressure, LDL cholesterol, HDL cholesterol, HbA1c, eGFR, use of statins, ACE-inhibitors/ATII RBA and aspirin/clopidogrel.

  • ACE, angiotensin converting enzyme; ATII RBA, ATII receptor blocking agents; BMI, body mass index; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein; MCI, myocardial infarction; PAD, peripheral artery disease; 3-point MACE, major cardiovascular endpoint (including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke); T2DM, type 2 diabetes mellitus.